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Abstract 1 
 2 
Background & aims: The purpose of the study was to determine which of the active constituents of fish 3 
oil, eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), is most effective in suppressing 4 
proinflammatory mediator generation and cytokine expression from LPS-stimulated human asthmatic 5 
alveolar macrophages (AM).  6 
Methods: The AM were obtained from twenty one asthmatic adults using fiberoptic bronchoscopy. 7 
Cells were pretreated with DMEM, pure EPA, an EPA-rich media (45% EPA/10% DHA), pure DHA, a 8 
DHA-rich media (10% EPA/50% DHA) or LipovenosR (n-6 PUFA), and then exposed to Dulbecco’s 9 
Modified Eagle’s Medium (DMEM) (-) or LPS (+). Supernatants were analyzed for leukotriene (LT)B4, 10 
prostaglandin (PG)D2, tumor necrosis factor (TNF)- and interleukin (IL)-1 production. Detection of 11 
TNF- and IL-1 mRNA expression levels were quantified by reverse transcriptase polymerase chain 12 
reaction.   13 
Results: 120 µM pure EPA and EPA-rich media significantly (p<0.05) suppressed TNF- and IL-1 14 
mRNA expression and the production of LTB4, PGD2 and TNF- and IL-1 in LPS-stimulated primary 15 
AM cells obtained from asthmatic patients to a much greater extent than 120 µM pure DHA and DHA-16 
rich media respectively.  17 
Conclusions: This study has shown for the first time that EPA is a more potent inhibitor than DHA of 18 
inflammatory responses in human asthmatic AM cells.  19 
 20 
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Introduction 1 
 2 
Over the past three decades there has been significant interest in the therapeutic potential of fish 3 
oils for various inflammatory conditions such as rheumatoid arthritis, inflammatory bowel diseases, and 4 
asthma.  Fish oil, rich in omega-3 (n-3) polyunsaturated fatty acids (PUFA), such as eicosapentaenoic acid 5 
(EPA) and docosahexaenoic acid (DHA), appear to have additional antiphlogistic properties primarily 6 
through their effects on the neutrophil and macrophage (M) component of the inflammatory response 1-7.   7 
Eicosapentaenoic acid can compete with arachidonic acid (AA), as a substrate for 8 
cyclooxygenase (COX)-2 and 5-lipoxyeganse (5-LO) enzymes and be converted to less inflammatory 9 
eicosanoids 6, 8. At present the mechanism(s) underpinning the anti-inflammatory effects of DHA are 10 
unclear, but may be related to altered gene transcription and translation via direct or indirect actions on 11 
intracellular signaling pathways 9-11. In addition, n-3 PUFA-derived mediators such as lipoxin, 12 
docosatrienes  resolvins and neuroprotectins may also have anti-inflammatory, pro-resolving and 13 
protective properties 12.  14 
The observational evidence on fish oil effects has been relatively consistent in demonstrating 15 
protection against asthma and/or allergy in relation to a high intake, and ecological and other cross-16 
sectional data support the hypothesis that n-6 PUFA may increase and n-3 PUFA may decrease asthma 17 
risk 13.  While the clinical data on the effect of fish oil supplementation in asthma has been equivocal 18 
14supplementing the diet with fish oil in individuals with exercise-induced asthma (EIA) has yielded 19 
promising results 15, 16. Our laboratory has shown that 3 weeks of fish oil supplementation reduced the 20 
severity of EIA, airway inflammation and bronchodilator use, and improved asthma symptoms scores in 21 
elite athletes 15 and asthmatic individuals 16. 22 
The majority of studies investigating the effects of n-3 PUFA on asthma/EIA have either 23 
employed fish oils rich in EPA or oils which contain a heterogeneous blend of EPA and DHA.  Only a 24 
few studies have examined the effects of supplementing asthmatic patients with pure EPA and/or DHA, 25 
with conflicting results 14.  Data is therefore insufficient to make recommendations for intake of specific 26 
n-3 PUFA in asthma, e.g. EPA versus DHA versus EPA + DHA combined 17. Although many studies 27 
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have investigated the effects of EPA and DHA on macrophage function in animal models and cell lines, 1 
there is little evidence about the effects of these lipids on primary human macrophages obtained from 2 
asthmatic patients.   3 
Therefore, the main aim of this study was to compare the individual effects of EPA and DHA, 4 
and a variety of heterogeneous blends of EPA and DHA, on eicosanoid and cytokine generation from 5 
LPS-stimulated human asthmatic alveolar macrophages (AM).  In addition, the effects of EPA and DHA 6 
on cytokine mRNA expression were investigated in the LPS-stimulated AM.  7 
 8 
Methods 9 
 10 
Twenty non-smoking adults with asthma were recruited to this study. Asthma was diagnosed by a 11 
history of recurrent wheezing and chest tightness and a previous physician diagnosis. All subjects had 12 
clinically treated mild-to- moderate persistent asthma, with an FEV1 greater than 70% of predicted 18. 13 
Inhaled corticosteroids, 5-lipoxygenase inhibitors and leukotriene receptor antagonists were withheld for 14 
4 weeks prior to fiberoptic bronchoscopy. Subjects were also excluded if they had a history of taking n-3 15 
PUFA supplements or consumed more than one fish meal per week. A group of nonasthmatic (control) 16 
subjects was not included in the present study as it has been shown that fish oil supplementation does not 17 
alter pulmonary function or inflammatory mediator generation in this population 15. The local Institutional 18 
Research Ethics Committee approved the study protocol.    19 
 20 
Fiberoptic Bronchoscopy.  21 
Fiberoptic bronchoscopy was used to obtain BALF from each subject. Using local anesthesia with 22 
lidocaine (2% wt/vol) to the upper airways and larynx, a fiberoptic bronchoscope was passed through the 23 
nasal passages into the trachea. The bronchoscope was wedged in the right middle lobe and 4 × 60-ml 24 
aliquots of prewarmed sterile 0.9% NaCl solution were instilled. This solution was aspirated through the 25 
bronchoscope, collected in prechilled glass bottles, and stored on ice and processed within 30 min.   26 
 27 
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Separation of AM from BALF.  1 
AM cells were separated from BALF using previously described methods, with slight 2 
modifications 19. Briefly, the BALF was filtered through a single layer of coarse sterile gauze to remove 3 
mucus clumps and then centrifuged at 1,000 g for 10 min at 4° C to obtain a cell pellet. The cell pellet was 4 
washed once in 50 ml of Ca2+/ Mg2+ free Hanks' balanced salt solution (HBSS). The cells were counted on 5 
a hemocytometer slide using a Kimura counterstain and viability assessed by the trypan blue exclusion 6 
test. Cytospins were performed, using 104 cells per slide, and stained with May-Grunwald-Giemsa in 7 
order to obtain differential cell counts (Table 1). The remaining cells were resuspended at a concentration 8 
of 2 × 106 AM per milliliter in RPMI 1640 medium supplemented with 10% (vol/vol) fetal calf serum, 9 
2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. 2 × 106 AM/well were plated onto 10 
6-well plates and allowed to adhere for 90 min in a humidified incubator in 95% air, 5% CO2 (vol/vol), at 11 
37° C. Nonadherent cells were removed by washing three times with RPMI 1640 medium, leaving the 12 
adherent macrophages. The resulting AM population was > 95% pure, as assessed by staining and 13 
morphologic analysis. The AM from each individual were harvested with a cell scraper and combined 14 
into one aliquot.   15 
 16 
Experimental Design.  17 
Cells were divided into six treatment groups, pure EPA [cis-5, 8, 11, 14, 17-eicosapentanoic acid 18 
(Sigma-Aldrich, St. Louis, MO)], an EPA-rich media [(EPAX 4510 TG (45% EPA/10% DHA) (Pronova 19 
Biocare, Lysaker, Norway)], pure DHA [cis-4, 7, 10, 13, 16, 19-docosahexanoic acid (Sigma-Aldrich, St. 20 
Louis, MO)], a DHA-rich media [(EPAX 1050 TG (10% EPA/50% DHA) (Pronova Biocare, Lyasker, 21 
Norway)], Lipovenos® (Fresenius-Kabi, Bad-Homburg, Germany: an n-6 PUFA) or Dulbecco’s 22 
Modified Eagle’s Medium (DMEM) (control media).  23 
All fatty acids were dissolved in distilled H2O, aliquoted, and stored under an N2 stream, and 24 
stored at -80oC for no longer than 1 week prior to use.  EPAX 4510 TG is a triglyceridic oil containing 25 
approximately 45% EPA and 10% DHA, with saturated fatty acids and monounsaturated fatty acids 26 
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comprising 9-12% and 20-24% respectively. EPAX 1050 TG is triglyceridic oil containing approximately 1 
10% EPA and 50% DHA, with saturated fatty acids and monounsaturated fatty acids comprising 2-10% 2 
and 5-15% respectively.  3 
AM cells were suspended in Dulbecco’s modified Eagle’s medium (DMEM) (Mediatech, 4 
Herndon, VA), supplemented with 10% heat inactivated endotoxin-free fetal bovine serum (FBS, 5 
Intergen), 100 U/ml penicillin, and 100 U/ml streptomycin (GIBCO-BRL) and incubated at 37oC in 5% 6 
CO2. In all experiments, cells were plated in 24-well plates at a density of 1 x 106 cells/well and allowed 7 
to adhere for 2 hr and then incubated with either a high-dose (120µM) or low dose (25µM) (of a 100mM 8 
stock solution) of pure EPA, pure DHA, EPAX 4510, EPAX 1050 or LipovenosR (n-6 PUFA) for 4 hr 2, 9 
20
. The medium was then aspirated and the cells rinsed with 10 ml of sterile PBS twice. After washing the 10 
pure EPA, pure DHA, EPAX 4510 TG, EPAX 1050 TG or LipovenosR media from the plates, fresh 11 
DMEM supplemented with 10% FBS and L-glutamine was used to carry out all subsequent incubations 12 
with or without LPS. The cells were then stimulated with LPS (1g/ml) (BD Diagnostics, Sparks, MD) or 13 
incubated with medium alone for 3 hr 20. The supernatant was gently aspirated and stored at -70oC for 14 
subsequent competitive enzyme immunoassay (EIA) analysis of leukotriene (LT) B4 (Cayman Chemical, 15 
Ann Arbor, MI), prostaglandin (PG) D2- methoxime (MOX) (Cayman Chemical, Ann Arbor, MI), tumor 16 
necrosis factor (TNF)- (Cayman Chemical, Ann Arbor, MI), and interleukin (IL)-1 (Cayman Chemical, 17 
Ann Arbor, MI) using previously described methods16. Because PGD2 is a relatively unstable compound, 18 
we measured PGD2-MOX), a stable derivative of PGD2.    19 
 20 
Evaluation of cytokine mRNA expression 21 
Total RNA was isolated from macrophage monolayers using a commercially available kit 22 
(Qiagen, Valencia, CA) following the protocol provided. Detection of mRNA by real-time polymerase 23 
chain reaction was performed on an ABI-PRISM® 7700 Sequence Detector (Perkin-Elmer Applied 24 
Biosystems, Foster City, CA, USA) as previously described 10.  The TaqMan real-time PCR was 25 
performed on the cytokines TNF- and IL-1 using pre-developed assay reagent kits. All reagents 26 
7 
 
necessary for running a TaqMan real time PCR assay were purchased from Perkin-Elmer Applied 1 
Biosystems.  Each 25-µl reaction contained forward and reverse primers, 20 ng of cDNA, 2x TaqMan 2 
Universal PCR Mastermix and TaqMan probe.  The primers (Life Technologies, Grand Island, NY) and 3 
probes (Applied Biosystems, Foster City, CA) used in the TNF- assay were: forward primer, 5’- 4 
TGATCCGAGACGTGGAA -3’; reverse primer, 5’- ACCGCCTGGAGTTCTGGAA -3’;  and for the 5 
TaqMan Probe (5' 6-FAM, 3' TAMRA labeled), TGGCAGAAGAGGCACTCCCCCAA. For the IL-1 6 
assay: forward primer, 5’-CTGATGGCCCTAAACAGATGAAG – 3’; reverse, 5’-7 
GGTCGGAGATTCGTAGCAGCTGGAT – 3’; and for the TaqMan Probe (5' 6-FAM, 3' TAMRA 8 
labeled), ATGAACAACAAAAATGCCTCGTGCTGTCTG.  All reactions were performed in triplicate 9 
under the following conditions: 50oC for 2 min and 95oC for 10 min, followed by 40 cycles of 95oC for 15 10 
s and 60oC for 1 min.  Relative expression levels of IL-1 and TNF- mRNA were calculated using the 2-11 
CT
 method 21 after confirmation that the efficiency of the real-time PCR reaction was similar for the 2 12 
target genes over a range of template concentrations 22. The fold change for each target gene, normalized 13 
to GAPDH, was calculated for each sample using the equation x (amount of target) = 2-CT. The mean (+ 14 
SD) fold change in gene expression was then determined from the triplicate samples, and expressed 15 
relative to vehicle control (DMEM).   16 
 17 
Statistical Analysis 18 
Data were analyzed using the SPSS version 15 statistical software (SPSS Inc., Chicago, IL, 19 
USA). A one-way ANOVA was used to analyze the data .Where a significant F-ratio was found, Fisher’s 20 
protected least-square difference post-hoc test was used to detect differences in group means. All reported 21 
p-values were considered significant at the 0.05 level.  22 
 23 
 24 
 25 
 26
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Results 1 
The fluid recovered, total cell count and percent differential airway cell counts recovered from 2 
bronchial samples are presented in Table 1. The unstimulated AM cells did not demonstrate any 3 
significant differences (p>0.05) in LTB4, PGD2, TNF- or IL-1 production among the high dose (120 4 
µM) treatment groups (Figure 1, panel A-D).  DMEM pretreated controls demonstrated a significant 5 
increase (p<0.05) in LTB4, PGD2, TNF- and IL-1 production in response to LPS stimulation (Figure 1, 6 
panel A-D).  The inhibitory effect of 120 µM pure EPA on LPS-stimulated LTB4, PGD2, TNF- and IL-7 
1 production was significantly (p<0.05) greater than that of 120 µM pure DHA, EPAX4510, EPAX1050 8 
and LipovenosR. EPA and EPAX 4510 pretreatment significantly reduced (p<0.05) LPS-stimulated LTB4, 9 
PGD2, TNF- and IL-1 production by 84.6% and 66.3%, 81.7% and 60.5%, 90.2% and  72.9%, and 10 
88.2% and 73.6% respectively compared to DMEM pretreatment (Figure 1, panel A-D).   Similarly, 120 11 
µM pure DHA and EPAX 1050 pretreatment significantly decreased (p<0.05) LPS-stimulated LTB4, 12 
PGD2, TNF- and IL-1 production by 50.3%, 39.7%, 18.3%, 51.7% and 31.5%, 51.6% and 33.2% 13 
respectively compared to DMEM pretreatment (Figure 1, panel A-D). In contrast Lipovenos® had no 14 
significant (p>0.05) effect on LPS-induction of pro-inflammatory mediators compared to control cells 15 
(Figure 1, panel A-D).  16 
Since differences in LPS-stimulated eicosanoid and cytokine production were observed at the 17 
high dose (120 µM) we also examined whether these differences would be noticeable at a lower dose of 18 
n-3 PUFA (25µM).  Figure 2 (panel A-B) presents the effects of LPS-stimulated LTB4 and TNF- 19 
production  in AM cells pretreated with 25 µM pure EPA, pure DHA, EPAX4510, EPAX1050 and 20 
LipovenosR. The anti-inflammatory response at the 25µM dose followed a similar pattern as the 120µM 21 
n-3 PUFA dose, but had significantly (p<0.05) less of an inhibitory effect on LPS-stimulated AM LTB4 22 
and TNF- production (Figure 2, panel A-B).  A comparable effect was seen for LPS-stimulated PGD2 23 
and IL-1 production (data not shown).   24 
The effect of the high dose (120µM) and low dose (25µM) n-3PUFA was also examined at the 25 
transcriptional level. We investigated the effects of 25µM and 120µM pure DHA, EPAX4510, 26 
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EPAX1050 and LipovenosR on LPS-stimulated AM TNF- and IL-1 mRNA expression (Figure 3, 1 
panel A-B). The inhibitory effect of 120 µM pure-EPA on LPS-stimulated TNF- and IL-1 mRNA 2 
expression was significantly greater (p < 0.05) than that of 120 µM pure-DHA, EPAX4510, EPAX1050 3 
and LipovenosR (Figure 3, panel A). Interestingly, the effect of 25 µM n-3 PUFA on LPS-stimulated 4 
TNF- and IL-1 mRNA expression followed a similar pattern to the 120µM pretreated cells (Figure 3, 5 
panel A) but had significantly less (p < 0.05) of an inhibitory effect (Figure 3, panel B).  6 
 7 
Discussion 8 
This study has demonstrated for the first time that pure EPA media reduced TNF- and IL-1 9 
mRNA expression and the production of LTB4, PGD2 and TNF- and IL-1 from LPS-stimulated primary 10 
AM cells obtained from asthmatic patients to a much greater extent than pure DHA. Interestingly, the 11 
EPA-rich media (EPAX 4510) significantly reduced cytokine mRNA expression and generation of 12 
eicosanoids and cytokines from LPS-stimulated AM cells to a much greater degree than both the pure 13 
DHA and the DHA-rich media (EPAX 1050), suggesting that the greater the EPA content of an n-3 14 
PUFA formulation the greater the eicosanoid and cytokine reduction. Whilst these experiments were 15 
conducted at a comparatively high n-3 PUFA dose (120 µM) we also observed a similar pattern of LPS-16 
stimulated AM cytokine and eicosanoid production and cytokine mRNA expression inhibition on a 17 
much lower n-3 PUFA concentration (25 µM). Although our findings agree with a number of human 18 
studies that have shown that fish oil suppressed cytokine production in LPS-stimulated mononuclear cells 19 
4, 23, 24
, other studies have not shown this response 25-27.  20 
While there are a few studies that have assessed the efficacy of n-3 PUFA on cytokine production 21 
using human THP-1 monocytes 10, 28, 29 and murine macrophages 2, 7, 20, our study is the first to assess the 22 
efficacy of a variety of n-3 PUFA blends on eicosanoid and cytokine production from AM obtained 23 
directly from human asthmatic patients.   Our data, for the most part, agree and expand the few studies 24 
that have examined either the individual or combined effects of EPA and DHA on macrophage function 25 
in vitro.  Lo et al. 7 observed a reduction in TNF- production and mRNA expression in LPS-stimulated 26 
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murine RAW macrophage  incubated in the presence of 114 µM EPA for 24 h. Similarly Zhao et al. 30 has 1 
shown that LPS-stimulated human THP-1 monocytes pretreated with 60µM EPA for 24 h significantly 2 
decreased TNF- production and mRNA expression.  In contrast Zhao et al. 31 has shown in a follow-up 3 
study that human THP-1 monocytes pretreated with 100µM DHA for 24 h significantly reduced LPS 4 
(1µg/ml)-stimulated IL-6, IL-1 and TNF- production and mRNA expression. Chu and coworkers 28 5 
have reported using low doses of EPA (10µM) and DHA (10µM) significantly reduced TNF- and IL- 6 
generation from LPS-stimulated human THP-1 monocytes.  It has been demonstrated that murine RAW 7 
264.7 macrophages pretreated for 4 h with Omegaven®, a high purity emulsion containing 1.25 - 2.82 g 8 
EPA and 1.44 - 3.09 g DHA, resulted in a significant suppression of LPS (1µg/ml)-stimulated TNF- 9 
production by 48% 2 and TNF- mRNA expression by 47% 20 compared to control media, while 10 
Lipovenos® ( an n-6 PUFA emulsion) did not alter cytokine production compared to control medium 11 
alone.    12 
Recently Weldon et al. 10 sought to investigate the differential effects of pure EPA and DHA on 13 
cytokine expression from activated human THP-1 monocyte-derived macrophages in vitro.  Equivalent 14 
doses of EPA and DHA significantly decreased LPS-stimulated THP-1 monocyte TNF-, IL-1 and 15 
TNF- production and mRNA expression compared to control cells. However, whether at a relatively 16 
high dose (100µM) or low dose (25µM), DHA had a much greater inhibitory effect on cytokine 17 
production and mRNA expression than the equivalent EPA dose.   This is in contrast with the findings 18 
from the present study which found that EPA at a high and low dose had a significantly greater inhibitory 19 
effect on LPS-stimulated human AM LTB4, PGD2, TNF-- and IL- generation and TNF-- and IL- 20 
mRNA expression compared to a comparable DHA dose.  The divergent findings between the present 21 
study and the Weldon et al.10 study are difficult to reconcile, but may in part be related to the use of 22 
different cell types used. For example, the present study used primary human AM taken directly from 23 
the airways of asthmatic patients, whereas the cell line used in the experiments by Weldon et al. 10 were 24 
human THP-1 monocytes, which although may behave like native monocyte –derived macrophages in 25 
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comparison to other human myeloid cell lines, may express a different physiologic response compared to 1 
primary human AM when exposed to a n-3 PUFA.        2 
The present study has demonstrated that n-3 PUFA inhibits LTB4 and PGD2 from LPS-stimulated 3 
human AM.  Our results concur with several studies in which dietary supplementation with EPA and 4 
DHA reduced inflammatory eicosanoids such as products generated via the 5-lipoxygenase pathway of 5 
neutrophils and monocytes and an attenuation of LTB4-mediated chemotaxis6, and decreased PGE2 6 
production in LPS-stimulated murine RAW 264.7 cells pretreated with Omegaven® compared to control 7 
cells3.  8 
In the present study we evaluated the release of particular proinflammatory eicosanoids, derived 9 
from both the cyclooxygenase (COX) and 5-lipoxygenase (5-LO) pathway such as PGD2 and LTB4, and a 10 
few key proinflammatory cytokines (IL-1 and TNF-) that have been directly implicated in the 11 
pathogenesis of asthma.  LTB4 is a potent neutrophil chemoattractant factor in the airways 32, while PGD2 12 
is a potent bronchoconstrictor and is thought to play a role in pathogenesis of asthma, in particular during 13 
the early asthmatic response to allergen 33. IL-1 induces airway neutrophilia, and increased expression of 14 
IL-1 in asthmatic airway epithelium has been reported, together with an increased an increased number 15 
of AM expressing IL-1 34. TNF- is also released from AM from asthmatic patients after allergen 16 
challenge 35, and may have an important amplifying effect in asthmatic inflammation 36.  Since, both IL-17 
1 and TNF- both activate and are activated by nuclear factor-kappaB (NF-B), this positive regulatory 18 
loop may amplify and perpetuate the asthmatic inflammatory response 37.  19 
Our findings indicate that that EPA is a more potent inhibitor than DHA of LPS-stimulated 20 
eicosanoid and cytokine generation from human asthmatic AM. At present the data from the few studies 21 
assessing the comparative effects of EPA and DHA on in vitro inflammatory mediator generation is 22 
equivocal.   Khalfoun et al. 38 have demonstrated a more potent inhibition of IL-6 from LPS-stimulated 23 
lymphocytes on EPA compared to DHA, while Weldon et al. 10 more recently demonstrated a more potent 24 
inhibition on DHA compared with EPA in inhibiting LPS-stimulated human THP-1 monocyte cytokine 25 
production. On the other hand Moon et al. 39 observed no difference between EPA and DHA on IL-6 26 
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secretion from murine macrophages, and Chu et al. 28 observed no difference between EPA and DHA on 1 
TNF- and IL-1 production from human THP-1 monocyctes.  2 
The biological mechanisms underpinning the more potent anti-inflammatory effects of EPA 3 
compared to DHA in the present study may be related to diverse mechanisms of action.  EPA can cause 4 
dual inhibition of cyclooxygenase (COX)-2 and 5-lipoxygenase (LOX) pathways.   EPA is a much less 5 
preferred substrate compared with AA for both pathways, and generally by substrate competition inhibits 6 
release of AA derived eicosanoids, thus reducing the generation of proinflammatory ‘tetraene’ 4-series 7 
leukotrienes (LTs) and 2-series prostanoids, and production of cytokines from inflammatory cells 6, 8. 8 
EPA- derived metabolites have lower biological activity compared to their analogous AA-derivatives 40. 9 
We have previously shown that a fish oil diet decreased LTB4 and increased LTB5 generation from 10 
activated polymorphonuclear leukocytes obtained from asthmatic patients 16.  In addition, the anti-11 
inflammatory effects of EPA may occur by modulating intracellular signal pathways which, in turn, 12 
influence gene activation and cytokine production. Lo and coworkers 7 showed that RAW macrophages 13 
incubated in EPA-rich media altered NF-B activity (suppression of p65/p50 dimer), while Zhao et al. 30 14 
demonstrated that EPA inhibited LPS-induced NF- B activation in human THP-1 monocyctes.  15 
Lipopolysaccharide stimulation of monocytes activates several intracellular pathways, including IB 16 
kinase and mitogen-activated kinase (MAPK) pathways (ERK, JNK and p38). These signaling pathways 17 
activate a variety of transcription factors such as NF-B and activator-protein 1 (AP-1), leading to the 18 
activation of cytokine gene expression 41. It has been reported that LPS-stimulated CD14 expression and 19 
toll-like receptor (TLR)-4-induced signaling pathways are down-regulated by n-3 PUFA 42, providing 20 
mechanisms through which EPA may exert its effects on both AP-1 and NF-B activation.     21 
Although DHA may have similar anti-inflammatory effects as EPA, it does not act by direct 22 
competition with AA.  DHA can decrease the release of AA from membrane phospholipids by  23 
decreasing phospholipase A2 activity, and decreasing the responsiveness of TLR-4 to LPS, thereby 24 
suppressing NF-B activation and subsequent inflammatory gene transcription 11.  Komatsu et al. 43 has 25 
shown that 60 µM of DHA inhibited NF-B activity in interferon- and LPS-stimulated RAW 26 
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macrophages, while Weldon et al. recently demonstrated that DHA was more effective than EPA in 1 
inhibiting p65 expression and increased IB expression in LPS-stimulated THP-1 monocytes. 2 
Interestingly, Novak and coworkers 20 have reported reduced LPS-stimulated RAW macrophage NF-B 3 
activity pre-treated with an n-3 PUFA lipid emulsion (Omegaven®).  The inhibition of NF-B activity by 4 
either EPA or DHA is important especially since AM and bronchial epithelial cells from stable 5 
asthmatics exhibit increased NF-B activity compared with cells from healthy individuals 37, and 6 
therefore it has been suggested that NF-B plays a pivotal role in the pathogenesis of asthma 37, 44.   7 
Interestingly, Li and coworkers 45 recently demonstrated that EPA and DHA down-regulate LPS-8 
induced activation of NF-B via a peroxisome proliferator-activated receptor (PPAR)--dependent 9 
pathway in human kidney cells. These results suggest that PPAR- activation by EPA and DHA may be 10 
one of the underlying mechanisms for the beneficial effects of fish oil. Due to the fact that a new class of 11 
mediator families derived from fish oil, the EPA-and DHA-derived resolvins (RvE1 and RvD1) and the 12 
DHA-derived protectin (PD1), which act locally, and possess potent anti-inflammatory novel bioactions, 13 
suggest potentially novel therapeutic treatment strategies for asthma  12. In addition, since we have 14 
previously shown that the amount of LTB5 generated from activated PMNLs was markedly 15 
increased following fish oil supplementation in asthmatic patients 16, further studies should 16 
investigate the effect of fish oil on EPA and DHA- derived (anti-inflammatory) mediators 17 
generated from human asthmatic AM 46.  18 
In conclusion the present study has shown for the first time that EPA is a more potent inhibitor 19 
than DHA of inflammatory responses in human asthmatic AM cells. In addition, the present study has 20 
shown that the greater the EPA content of a fish oil formulation the greater the inhibition of the 21 
inflammatory response. Elucidating the mechanism of this modulation could help us to understand how 22 
dietary n-3 PUFA achieves their specific effects on airway inflammation in asthmatic individuals. The 23 
clinical relevance of the present study, along with previous work from our group 15, 16, suggest that EPA-24 
rich fish oil may provide a therapeutic option for adults with asthma. In view of the clinical consequences, 25 
14 
 
these findings point towards prophylactic and acute therapeutic effects of fish oil supplementation in 1 
inflammatory diseases such as asthma. It is possible that pharmacotherapy could be decreased in some 2 
patients with asthma in concert with increased fish-oil ingestion if both the drug and n-3 PUFA are 3 
exerting their therapeutic effects through the same molecular actions.    4 
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Figure Legends 1 
 2 
Figure 1. Effect 120 µM EPA-rich media (EPAX 4510), pure EPA, pure DHA, DHA-rich media (EPAX 3 
1050) and LipovenosR (n-6 PUFA) on LTB4 (panel A), PGD2 (panel B), TNF- (panel C) and IL-1 4 
(panel D) production by LPS-stimulated human AM. The data represent mean + SD from six separate 5 
experiments, each done in triplicate. * p < 0.05 vs. DMEM + LPS.    p < 0.05 vs. 25 µM treatment 6 
within each inflammatory mediator.  A difference in letter (a through e) designates significant differences 7 
(p<0.05) between treatments (EPAX 4510, EPA, DHA, EPAX 1050 and Lipovenos®).    8 
 9 
Figure 2.  Effect 25 µM EPA-rich media (EPAX 4510), pure EPA, pure DHA, DHA-rich media (EPAX 10 
1050) and LipovenosR (n-6 PUFA) on LTB4 (panel A) and TNF- (panel B) production by LPS-11 
stimulated human AM. The data represent mean + SD from six separate experiments, each done in 12 
triplicate. * p < 0.05 vs. DMEM + LPS.  A difference in letter (a through e) designates significant 13 
differences (p<0.05) between treatments (EPAX 4510, EPA, DHA, EPAX 1050 and Lipovenos®).    14 
 15 
Figure 3. Effect 120 µM (panel A) and 25 µM (panel B) EPA-rich media (EPAX 4510), pure EPA, pure 16 
DHA, DHA-rich media (EPAX 1050) and LipovenosR (n-6 PUFA) on TNF- and IL-1 mRNA levels in 17 
LPS-stimulated human alveolar macrophages.  TNF- and IL-1 mRNA levels were normalized to GAPDH 18 
and expressed relative to DMEM.  The data represent mean + SD. * p < 0.05 relative to DMEM.  p < 19 
0.05 vs. 25 µM treatment within each cytokine. A difference in letter (a through e) designates a 20 
significant difference (p<0.05) between each treatment (EPAX 4510, EPA, DHA, EPAX 1050 and 21 
Lipovenos®).   22 
 23 
 24 
 25 
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 28 
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